Sfoglia per AUTORE
CAVO M
Collezione AO Cuneo

  

Items : 8

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Visco C; Corradini P; Passamonti F; Bertù L; Gherlinzoni F; Pagano L; Guidetti A; Cilloni D; Visani G; Federici AB; Tisi MC; Cudillo L; Galimberti S; Coviello E; Della Porta MG; Mohamed S; Mauro FR; Gentile M; Gambacorti-Passerini C; Massaia M; Bocchia M; Billio A; Cattaneo C; Derenzini E; Scattolin A; Marchesi F; Fracchiolla NS; Arcaini L; Trentin L; et alii...

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Corradini P; Merli F; Passamonti F; Candoni A; Krampera M; Venditti A; Selleri C; Tosi P; Lanza F; Conconi A; La Barbera EO; Gambacorti-Passerini C; Visani G; Vallisa D; Rigacci L; Armiento D; Gherlinzoni F; Tafuri A; Galimberti S; Bocchia M; Corso A; Cilloni D; Cardinali V; Turrini M; Trentin L; Cuneo A; Della Porta M; Massaia M; Fracchiolla N; et alii...

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.

2022
AO Cuneo
AOU Città della Salute di Torino

Corradini P; Passamonti F; Antonio Grossi P; Bruno R; Pagano L; Luppi M; Busca A; Giuliani N; Corso A; Mohamed S; Tosi P; Giovanni Della Porta M; Lanza F; Rigacci L; Massimo Lemoli R; Venditti A; Tafuri A; Billio A; Gentile M; Falini B; Turrini M; Chiara Tisi M; Morotti A; Coviello E; Trentin L; Bocchia M; Galimberti S; Cuneo A; Musto P; et alii...

Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.

2021
AO Cuneo

Zamagni E; Nanni C; Dozza L; Carlier T; Bailly C; Tacchetti P; Versari A; Chauvie S; Gallamini A; Gamberi B; Caillot D; Patriarca F; Macro M; Boccadoro M; Garderet L; Barbato S; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Cavo M; Bodet-Milin C; Moreau P; Kraeber-Bodéré F; Zamagni E; Nanni C; Dozza L; Carlier T; et alii...

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.

2020
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Corradini P; Pagano L; Bertù L; Corrao G; Grossi PA; Franchi M; Oberti M; Zappasodi P; Visco C; Armiento D; Pane F; Pinto A; Galieni P; Rigacci L; Candoni A; Venditti A; Fava C; Federici AB; Marchesi F; Musto P; Gentile M; Bocchia M; Di Renzo N; Olivieri A; Ferrandina C; Selleri C; Ortu La Barbera E; Luppi M; Scattolin AM; et alii...

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21

2018
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Ghedini P; Cavo M; Gamberi B; Gay F; Patriarca F; Gallamini A; Bellò M; Bertone E; Rensi M; Bianchi A; Chauvie S; Nanni C; Versari A; Zamagni E;

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.

2016
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Gamberi B; Cavo M; Gay F; Patriarca F; Gallamini A; Rambaldi I; Rensi M; Bellò M; Bianchi A; Versari A; Chauvie S; Zamagni E; Nanni C;